NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Oligodendroglioma


Return to Library

Free Oligodendroglioma Articles


New oligodendroglioma study findings recently were published by researchers at Kaiser Permanente



2009 JUL 13 - (NewsRx.com) -- "Oligodendroglioma of the spinal cord is a rare tumor that most often presents with spinal cord symptoms. The authors present a case of spinal cord oligodendroglioma that was associated with cerebral rather than spinal cord symptoms," investigators in the United States report.

"A 30-year-old woman developed nausea, vomiting, and severe headaches. Magnetic resonance imaging of the brain showed meningeal enhancement. The patient underwent a craniotomy with biopsies of the meninges and brain. The biopsy findings revealed an abnormal arachnoid thickening without tumor cells. The patient later developed hydrocephaluss and underwent shunt placement. Cerebrospinal fluid cytological findings were negative for tumor cells or infection. She was found to have a cervical cord lesion at C3-4 that was initially nonenhancing but later enhanced after Gd administration. Biopsy of the cord lesion with partial resection showed a WHO Grade 11 oligodendroglioma with 1p and 19q deletions determined by fluorescence in situ hybridization. Neurooncological treatment with tumor radiation and temozolomide (Temodor) resulted in improvement in radiographic findings, symptoms, and long-term survival. This paper presents an extensive review of the literature, which revealed only 2 other reported cases of cerebral symptoms in adults that preceded spinal cord symptoms in a patient with oligodendroglioma of the spinal cord," wrote K.H. Guppy and colleagues, Kaiser Permanente.

The researchers concluded: "It is also the first reported case of oligodendroglimatosis due to a cervical spinal cord oligodendroglioma with I p and 19q deletions. (DOI: 10.3171/2009.2.SPINE08853)."

Guppy and colleagues published their study in the Journal of Neurosurgery - Spine (Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis Case report. Journal of Neurosurgery - Spine, 2009;10(6):557-563).

For additional information, contact K.H. Guppy, University of California, Dept. of Neurosurgery, Kaiser Permanente Med Group, 2025 Morse Avenue, Sacramento, CA 95825, USA.

The publisher of the Journal of Neurosurgery - Spine can be contacted at: American Association Neurological Surgeons, 5550 Meadowbrook Drive, Rolling Meadows, IL 60008, USA.

Keywords: United States, Sacramento, Biopsy, Central Nervous System Disease, Craniotomy, Drugs, Headache, Hydrocephalus, Magnetic Resonance, Nausea, Neurology, Neurosurgery, Oligodendroglioma, Pharmaceuticals, Surgery, Temozolomide, Therapy, Treatment, Vomiting, Kaiser Permanente.

This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2009, Pain & Central Nervous System Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login